Insider · CIK 0001828724
Adrian Gottschalk
Files at FHTX (Foghorn Therapeutics Inc.). First filing -, latest -.
In brief
Adrian Gottschalk files SEC Form 4 as CEO and director at FHTX (Foghorn Therapeutics Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Adrian Gottschalk has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 10 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Apr 9, 2026 | FHTX Foghorn Therapeutics Inc. | GGift Common Stockindirect: By 2023 GRAT | -47,497 | $0.00 | $0 | 0 | Apr 13, 2026 |
| Apr 9, 2026 | FHTX Foghorn Therapeutics Inc. | GGift Common Stockindirect: By Living Trust | +47,497 | $0.00 | $0 | 211,704 | Apr 13, 2026 |
| Apr 10, 2026 | FHTX Foghorn Therapeutics Inc. | GGift Common Stockindirect: 2025 GRAT | -59,208 | $0.00 | $0 | 240,792 | Apr 13, 2026 |
| Apr 10, 2026 | FHTX Foghorn Therapeutics Inc. | GGift Common Stockindirect: By Living Trust | +59,208 | $0.00 | $0 | 270,912 | Apr 13, 2026 |
| Feb 5, 2026 | FHTX Foghorn Therapeutics Inc. | AGrant or award Stock option (right to buy)derivative | +1,075,000 | $5.23 | $5.6M | 1,075,000 | Feb 6, 2026 |
| Apr 25, 2025 | FHTX Foghorn Therapeutics Inc. | GGift Common Stockindirect: See Footnote | -300,000 | $0.00 | $0 | 511,704 | Apr 28, 2025 |
| Apr 25, 2025 | FHTX Foghorn Therapeutics Inc. | GGift Common Stockindirect: See Footnote | +300,000 | $0.00 | $0 | 511,704 | Apr 28, 2025 |
| Apr 9, 2025 | FHTX Foghorn Therapeutics Inc. | GGift Common Stockindirect: See Footnote | -197,906 | $0.00 | $0 | 511,704 | Apr 10, 2025 |
| Apr 9, 2025 | FHTX Foghorn Therapeutics Inc. | GGift Common Stockindirect: See Footnote | +197,906 | $0.00 | $0 | 511,704 | Apr 10, 2025 |
| Jan 22, 2025 | FHTX Foghorn Therapeutics Inc. | AGrant or award Stock Option (right to buy)derivative | +400,000 | $4.37 | $1.7M | 400,000 | Jan 24, 2025 |
Questions about Adrian Gottschalk
Answered from the filings on this page, as of the latest one.
Is Adrian Gottschalk buying or selling?
Adrian Gottschalk has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Adrian Gottschalk's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Adrian Gottschalk has 0.
Where does Adrian Gottschalk file Form 4?
Adrian Gottschalk has filed Form 4 at FHTX (Foghorn Therapeutics Inc.) as Chief Executive Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.